CN118401243A - 治疗神经退行性疾病的方法 - Google Patents

治疗神经退行性疾病的方法 Download PDF

Info

Publication number
CN118401243A
CN118401243A CN202280074008.5A CN202280074008A CN118401243A CN 118401243 A CN118401243 A CN 118401243A CN 202280074008 A CN202280074008 A CN 202280074008A CN 118401243 A CN118401243 A CN 118401243A
Authority
CN
China
Prior art keywords
methyl
pyrimidin
chloro
amine
aminopropyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280074008.5A
Other languages
English (en)
Chinese (zh)
Inventor
S·J·巴拉萨
J·K·特里默
Y·余
X·张
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PTC Therapeutics Inc
Original Assignee
PTC Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PTC Therapeutics Inc filed Critical PTC Therapeutics Inc
Publication of CN118401243A publication Critical patent/CN118401243A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202280074008.5A 2021-09-07 2022-09-06 治疗神经退行性疾病的方法 Pending CN118401243A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163260944P 2021-09-07 2021-09-07
US63/260,944 2021-09-07
PCT/US2022/075969 WO2023039370A1 (en) 2021-09-07 2022-09-06 Methods for treating neurogenerative diseases

Publications (1)

Publication Number Publication Date
CN118401243A true CN118401243A (zh) 2024-07-26

Family

ID=85506888

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280074008.5A Pending CN118401243A (zh) 2021-09-07 2022-09-06 治疗神经退行性疾病的方法

Country Status (7)

Country Link
US (1) US20240374602A1 (https=)
EP (1) EP4398988A4 (https=)
JP (1) JP2024533264A (https=)
CN (1) CN118401243A (https=)
CA (1) CA3231001A1 (https=)
MX (1) MX2024002887A (https=)
WO (1) WO2023039370A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202108519TA (en) 2019-02-13 2021-09-29 Ptc Therapeutics Inc Thioeno[3,2-b] pyridin-7-amine compounds for treating familial dysautonomia
WO2020167624A1 (en) 2019-02-13 2020-08-20 Ptc Therapeutics, Inc. Pyrrolo[2,3-d]pyrimidine compounds for treating familial dysautonomia

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1470356A1 (de) * 1964-01-15 1970-04-30 Thomae Gmbh Dr K Neue Thieno[3,2-d]pyrimidine und Verfahren zu ihrer Herstellung
US5654307A (en) * 1994-01-25 1997-08-05 Warner-Lambert Company Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
WO2004065392A1 (en) * 2003-01-24 2004-08-05 Smithkline Beecham Corporation Condensed pyridines and pyrimidines and their use as alk-5 receptor ligands
WO2012012656A2 (en) * 2010-07-21 2012-01-26 University Of South Florida Materials and methods for treating neurodegenerative diseases
CN115209955A (zh) * 2019-12-12 2022-10-18 Ptc医疗公司 治疗家族性自主神经功能障碍的化合物

Also Published As

Publication number Publication date
EP4398988A4 (en) 2025-07-09
JP2024533264A (ja) 2024-09-12
EP4398988A1 (en) 2024-07-17
CA3231001A1 (en) 2023-03-16
WO2023039370A1 (en) 2023-03-16
US20240374602A1 (en) 2024-11-14
MX2024002887A (es) 2024-05-28

Similar Documents

Publication Publication Date Title
EP4288441A1 (en) Methods for treating spinocerebellar ataxia type 3
US12398140B2 (en) Substituted pyrrolo [2,3-d]pyrimidines for treating familial dysautonomia
CN119997954A (zh) 用于治疗脊髓小脑性共济失调3型的化合物
US11377436B2 (en) EAAT2 enhancing molecules
US20200048267A1 (en) Oga inhibitor compounds
US12286420B2 (en) EAAT2 activators and methods of using thereof
EP4288059A1 (en) Compounds for treating spinocerebellar ataxia type 3
CN118401243A (zh) 治疗神经退行性疾病的方法
JP2025133750A (ja) 家族性自律神経失調症を処置するための化合物
EP2968995B1 (en) Inhibitors of lrrk2 kinase activity
US20210269442A1 (en) Fused ring derivative used as fgfr4 inhibitor
CN118251225A (zh) 治疗神经退行性疾病的方法
CN118019531A (zh) 用于治疗神经退行性疾病的方法
US12281116B2 (en) HTT modulators for treating Huntington's disease
US20240041886A1 (en) Methods for treating spinocerebellar ataxia type 3
US20250066356A1 (en) Lrrk2 inhibitors
WO2025213088A1 (en) Compounds, compositions, and methods
US20250270209A1 (en) Lrrk2 inhibitors
HK40042691B (en) Eaat2 activators and methods of using thereof
HK40042691A (en) Eaat2 activators and methods of using thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination